From shortest-path network assessment, being first-level interacting partners with three or more already known AD-related genes we conclude that connecting genes/proteins added by the Pathway Studio software such as ESRRA, NRF1, PTK2B, SRC and SRF could also be of potential interest in Alzheimer’s disease domain. This evidence concerns the gene NRF1 and Alzheimer disease.